35 Manufacturers Granted Licenses To Produce Generic Version Of Pfizer’s Covid Antiviral Pill For Developing Countries

35 Manufacturers Granted Licenses To Produce Generic Version Of Pfizer’s Covid Antiviral Pill For Developing Countries

Share to Linkedin Nearly three dozen pharmaceutical companies around the world have signed agreements to produce generic versions of Pfizer's oral Covid-19 antiviral medication nirmatrelvir, the United Nations-backed Medicines Patent Pool announced in a Thursday release, in an effort to bring the treatment to low- and middle-income countries. Manufacturers from early three dozen countries have reached agreements to produce generic versions ... [+] of Pfizer's oral Covid-19 antiviral medication Paxlovid. The agreement grants 35 manufacturers across 12 countries the ability to produce the raw components of nirmatrelvir or the finished version packaged with the anti-retroviral medication ritonavir. The U. S. Food and Drug Administration granted emergency use authorization to Pfizer in December for a combination of the two drugs that the company is marketing under the brand name Paxlovid to treat Covid in adults and children aged 12 and up. The nirmatrelvir sublicensing agreement will enable a generic version of Pfizer's treatment to be distributed in 95 low and middle-income countries, he MPP said. Chinese companies have signed five sublicenses, the most of any country, and a license will be granted to a Ukrainian manufacturer which can't currently sign the agreement due to the Russian invasion of the country. Clinical